Subscribe To
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
cellectis: end of 2023 data readouts to boost car-t prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its ...
November 3, 2023, 6:57 pm
Telephone and data systems, inc. (tds) q3 2023 earnings conference call transcript
Telephone and Data Systems, Inc. (NYSE:TDS ) Q3 2023 Earnings Conference Call November 3, 2023 10:00 AM ET Company Participants Colleen Thompson - VP,...
November 3, 2023, 3:37 pm
Intra-cellular (itci) q3 earnings top, product sales view raised
Intra-cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue t...
November 3, 2023, 1:32 pm
Papa john's (pzza) q3 earnings beat estimates, revenues lag
Papa John's (PZZA) fiscal third-quarter 2023 performance benefits from product innovation, operational excell<...
November 3, 2023, 12:47 pm
Omcl vs. prva: which stock should value investors buy now?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Privia...
November 3, 2023, 12:47 pm
Bruise treatment market size to reach usd 444 million by 2031, at a 3.5 % cagr | by tmr
Emerging trends in regenerative medicine and stem cell therapies are expected to offer innovative solut...
November 3, 2023, 12:30 pm
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Longeveron to report third quarter 2023 results and provide corporate update on november 10, 2023
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company d...
November 3, 2023, 12:00 pm
Why nikola shares charged higher this week
Nikola shored up its balance sheet in the third quarter. There's plenty of interest for Nikola's hydrogen fuel ...
November 3, 2023, 10:16 am
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T ...
November 3, 2023, 10:00 am
Swisscom in an excellent market position: q1-q3 2023
Group revenue stable, increase in operating income (EBITDA) and net income +++ Substantial investment in mobile communications and fixed networks +++ ...
November 3, 2023, 9:15 am
Omnicell (omcl) q3 earnings and revenues beat, margins down
Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environmen...
November 3, 2023, 9:02 am
American tower: near-term headwinds give rise to long-term value
American Tower is a top player in the cell tower REIT space, with a strong portfolio of communication s...
November 2, 2023, 11:49 pm
Abcellera biologics inc. (abcl) q3 2023 earnings call transcript
Abcellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Com...
November 2, 2023, 9:18 pm